Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy - PubMed

6 hours ago

Nirsevimab is highly effective in preventing RSV infection in healthy infants, but evidence among high-risk infants (preterm or with congenital heart disease) was limited.
A case-control study in Chile evaluated nirsevimab's association with preventing RSV-related hospitalizations after implementing a universal immunization strategy.
The study included at-risk infants hospitalized for RSV-related lower respiratory tract infection (LRTI) matched with non-hospitalized controls, all from nationwide registries during the 2024 RSV season.
Exposure was a single dose of nirsevimab given to infants born up to 6 months before April 1, 2024, and those born between April 1 and September 30, 2024.
Results showed nirsevimab was associated with an 84.3% reduced risk of RSV-related LRTI hospitalization among all at-risk infants, with higher reductions in some subgroups but not in extremely preterm infants alone.
The findings support replacing targeted palivizumab prophylaxis with a broader universal nirsevimab strategy for RSV prevention in high-risk infants.

Hasty Briefsbeta